Published: June 25, 2026 at 7:15 am
TRIMTECH Therapeutics’ seed round has topped £35 million.
The Cambridge biotechnology company is developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases.
It has raised another £11m led by Johnson & Johnson’s corporate venture capital organisation (Johnson & Johnson Innovation) and BGF.